Available Technology

Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists

Novel A3adenosine antagonists available for licensing. A3receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A3adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A3adenosine receptors have been implicated in asthma and glaucoma.
Patent Abstract: 
Novel A3adenosine antagonists available for licensing. A3receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A3adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A3adenosine receptors have been implicated in asthma and glaucoma. E-140-2008/1 Kenneth Jacobson(NIDDK)➽ more inventions... U.S. Pat:8,796,291issued 2014-08-05 PCT Application No. PCT/US2009/52439 US Application No. 13/056,997 Melman A, et al. Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem. 2008 Sep 15;16(18):8546-56.PMID 18752961 The NIDDK, Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A3adenosine receptor antagonists. Please contact Kenneth A. Jacobson, Ph.D. atkajacobs@helix.nih.govor Marguerite Miller atMarguerite.Miller@nih.govfor more information. Betty Tong, Ph.D. Email:tongb@niddk.nih.gov Phone: 301-451-7836 E-285-2008/0 Updated:Sep 8, 2016
Inventors: 
Kenneth Jacobson
Internal Laboratory Ref #: 
E-285-2008/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin